ALGN vs HOLX vs IDXX vs DXCM

For growth investors, DexCom, Inc.

(DXCM) is the stronger pick with 15. 6% revenue growth year-over-year, versus 0. 9% for Align Technology, Inc. (ALGN). DexCom, Inc. (DXCM) offers the better valuation at 29. 1x trailing P/E (24. 5x forward), making it the more compelling value choice. Analysts rate Align Technology, Inc. (ALGN) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, DexCom, Inc.

(DXCM) is the cheapest at 29. 1x versus IDEXX Laboratories, Inc. at 43. 7x. On forward P/E, Align Technology, Inc. is actually cheaper at 14. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: DexCom, Inc. wins at 2. 34x versus IDEXX Laboratories, Inc. 's 2. 76x.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -71. 9% for Align Technology, Inc. (ALGN). Over 10 years, the gap is even starker: IDXX returned +556. 2% versus ALGN's +122. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus Align Technology, Inc. 's 1. 66β — meaning ALGN is approximately 304% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Align Technology, Inc. (ALGN) carries a lower debt/equity ratio of 3% versus 67% for IDEXX Laboratories, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), DexCom, Inc.

(DXCM) is pulling ahead at 15. 6% versus 0. 9% for Align Technology, Inc. (ALGN). On earnings-per-share growth, the picture is similar: DexCom, Inc. grew EPS 47. 2% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, DXCM leads at 17. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus 10. 2% for Align Technology, Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus 15. 3% for ALGN. At the gross margin level — before operating expenses — ALGN leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, DexCom, Inc. (DXCM) is the more undervalued stock at a PEG of 2. 34x versus IDEXX Laboratories, Inc. 's 2. 76x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Align Technology, Inc. (ALGN) trades at 14. 9x forward P/E versus 39. 5x for IDEXX Laboratories, Inc. — 24. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IDXX: 35. 1% to $773. 13.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). Align Technology, Inc. (ALGN) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, ALGN: +122. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ALGN is a mid-cap quality compounder stock; HOLX is a mid-cap quality compounder stock; IDXX is a mid-cap quality compounder stock; DXCM is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.